Browse > Article

Prolyl Endopeptidase Inhibitory Activity of 6-O-Palmitoyl L-Ascorbic Acid  

Park, Yoon-Seok (College of Environment and Applied Chemistry and Plant Metabolism Research Center, Kyung Hee University)
Paik, Young-Sook (College of Environment and Applied Chemistry and Plant Metabolism Research Center, Kyung Hee University)
Publication Information
Journal of Applied Biological Chemistry / v.49, no.3, 2006 , pp. 110-113 More about this Journal
Abstract
Prolyl endopeptidase (PEP, EC 3.4.21.26, also referred to as prolyl oligopeptidase) degrades proline containing, biologically active neuropeptides such as vasopressin, substance P and thyrotropin-releasing hormone by cleaving peptide bonds on carboxyl side of prolyl residue within neuropeptides of less than 30 amino acids. Evaluation of PEP levels in postmortem brains of Alzheimer's disease patients revealed significant increases in PEP activity. Therefore, a specific PEP inhibitor can be a good candidate of drug against memory loss. Upon our examination for PEP inhibitory activity from micronutrients, ascorbic acid (vitamin C) showed small but significant PEP inhibition (13% PEP inhibition at $8{\mu}g{\cdot}ml^{-1}$). Palmitic acid showed almost no PEP inhibition. However, 6-O-palmitoyl ascorbic acid ($\underline{1}$) showed 70% PEP inhibition at $8{\mu}g{\cdot}ml^{-1}$ indicating that hydrophobic portion of the compound $\underline{1}$ may facilitate the inhibitory effect. $IC_{50}$ value of compound $\underline{1}$ was $12.6{\pm}0.2{\mu}M$. The primary and secondary Lineweaver Burk and Dixon plots for compound $\underline{1}$ indicated that it is a non-competitive inhibitor with inhibition constant (Ki) value of $23.7{\mu}M$.
Keywords
prolyl endopeptidase inhibitor; memory loss; 6-O-palmitoyl L-ascorbic acid; ascorbic acid; palmitic acid;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Aoyagi, T., Wada, T., Nagai, M., Kojima, F., Harada, S., Takeuchi, T., Takahashi, H., Hirokawa, K. and Tsumita, T. (1990) Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46, 94-97   DOI
2 Park, Y.-S., Jang, H.-J., Lee, K.-H., Hahn, T.-R. and Paik, Y.-S. (2006) Prolyl endopeptidase inhibitory activity of unsaturated fatty acids. J. Agric. Food Chem. 54, 1238- 1242   DOI   ScienceOn
3 Lee, J.-H., Lee, S.-Y., Lee, K.-S., Jang, H.-J., Lee, K.-H., Hahn, T.-R. and Paik, Y.-S. (2004) Prolyl endopeptidase inhibitors from the leaves of Ginkgo biloba. Planta Med. 70, 1228-1230   DOI   ScienceOn
4 Parle, M. and Dhingra, D. (2003) Ascorbic acid: a promising memory-enhancer in mice. J. Pharmacol. 93, 129-135   DOI
5 Kimura, K., Kawaguchi, N., Yoshihama, M. and Kawanishi, G.. (1990) Staurosporine, a prolyl endopeptidse inhibitor. Agric. Biol. Chem. 54, 3021-3022   DOI   ScienceOn
6 Odaka, C., Mizuochi, T., Shirasawa, T., Morain, P. and Checler, F. (2002) Murine T cells expressing high activity of prolyl endopeptidase are susceptible to activation-induced cell death. FEBS Lett. 512, 163-167   DOI   ScienceOn
7 Kalwant, S. and Porter, A. G.. (1991) Purification and characterization of human brain prolyl endopeptidase. Biochem. J. 276, 237-244   DOI
8 Morris, M. C., Beckett, L. A. and Scherr, P. A. (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alz. Dis. Assoc. Disord. 12, 121-126   DOI   ScienceOn
9 Duffy, S. J., Gokce, N., Holbrook, M., Huang, A., Frei, B., Keaney Jr, J. F. and Vita, J. A. (1999) Treatment of hypertension with ascorbic acid. The Lancet 354, 2048-2049   DOI   ScienceOn
10 Solfrizzi, V., Panza, F., Torres, F., Mastroianni, F., Del Parigi, A., Venezia, A. and Capurso, A. (1999) High monounsaturated fatty acids intake protects against agerelated cognitive decline. Neurology 52, 1563-1569   DOI   ScienceOn
11 Haag, M. (2003) Essential fatty acids and the brain. Can. J. Psychiatr. 48, 195-203   DOI
12 Padayatty, S. J. and Levine, M. (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J. Am. Coll. Nutr. 19, 423-425   DOI
13 Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radical Bio. Med. 23, 134-147   DOI   ScienceOn
14 Walter, R., Shlank, H., Glass, J. D., Schwartz, I. L. and Kerenyi, T. D. (1971), Leucylglycinamide released from oxytocin by human uterine enzyme. Science 173, 827-829   DOI   ScienceOn
15 Song, K.-S. and Raskin, I. (2002) A prolyl endopeptidaseinhibiting benzofuran dimer from Polyozellus multiflex. J. Nat. Prod. 65, 76-78   DOI   ScienceOn
16 Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten J. C., Hofman, A., Witteman, J. C. and Breteler, M. M. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. J. Amer. Med. Assoc. 287, 3223-3229   DOI   ScienceOn
17 Frank, B. and Gupta, S. (2005) A review of antioxidants and Alzheimer's disease. Ann Clin. Psychiatr.17, 269-286   DOI   ScienceOn
18 Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R. and White, L. R. (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265-1272   DOI   ScienceOn
19 Yoshimoto, T., Walter, R. and Tsuru, D. (1980) Proline-specific endopeptidase from Flavobacterium. Purification and properties. J. Biol. Chem. 255, 4786-4792
20 Park, Y.-S., Jang, H.-J. and Paik, Y.-S. (2005) Prolyl endopeptidase inhibitory activity of ursolic and oleanolic acids from corni fructus. Agric. Chem. Biotechnol. 48, 207- 212
21 Cunningham, D. F. and O'Connor, B. (1997) Proline specific peptidase. Biochem. Biophys. Acta 1343, 160-186   DOI   ScienceOn